FI3953357T3 - Koostumuksia ja menetelmiä KIT- ja PDGFRA-välitteisten sairauksien hoitoon - Google Patents
Koostumuksia ja menetelmiä KIT- ja PDGFRA-välitteisten sairauksien hoitoon Download PDFInfo
- Publication number
- FI3953357T3 FI3953357T3 FIEP20721083.2T FI20721083T FI3953357T3 FI 3953357 T3 FI3953357 T3 FI 3953357T3 FI 20721083 T FI20721083 T FI 20721083T FI 3953357 T3 FI3953357 T3 FI 3953357T3
- Authority
- FI
- Finland
- Prior art keywords
- hydrogen
- methyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 101150038994 PDGFRA gene Proteins 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 150000003921 pyrrolotriazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 201000008217 Aggressive systemic mastocytosis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000007033 Dysgerminoma Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- 201000009004 Indolent systemic mastocytosis Diseases 0.000 claims 1
- 206010073751 Intracranial germ cell tumour Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000032391 Smoldering systemic mastocytosis Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000000516 mast-cell leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833529P | 2019-04-12 | 2019-04-12 | |
| US201962911016P | 2019-10-04 | 2019-10-04 | |
| US201962930240P | 2019-11-04 | 2019-11-04 | |
| PCT/US2020/027177 WO2020210293A1 (en) | 2019-04-12 | 2020-04-08 | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3953357T3 true FI3953357T3 (fi) | 2024-07-15 |
Family
ID=70416596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20721083.2T FI3953357T3 (fi) | 2019-04-12 | 2020-04-08 | Koostumuksia ja menetelmiä KIT- ja PDGFRA-välitteisten sairauksien hoitoon |
Country Status (33)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109970745B (zh) | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| SG11202111244XA (en) | 2019-04-12 | 2021-11-29 | Blueprint Medicines Corp | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
| CN117098760B (zh) * | 2020-10-14 | 2026-04-14 | 缆图药品公司 | 用于治疗kit和pdgfra介导的疾病的组合物和方法 |
| WO2022081626A1 (en) * | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
| HU231413B1 (hu) | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Eljárás avapritinib és intermedierek előállítására |
| JP7763848B2 (ja) * | 2021-03-03 | 2025-11-04 | ブループリント メディシンズ コーポレイション | Ｋｉｔ－およびｐｄｇｆｒａ－媒介性疾患を治療するための化合物を製造するための合成方法および中間生成物 |
| WO2022192558A1 (en) | 2021-03-10 | 2022-09-15 | Blueprint Medicines Corporation | Salt and solid forms of a kinase inhibitor |
| CN117794935A (zh) * | 2021-03-10 | 2024-03-29 | 缆图药品公司 | 激酶抑制剂的盐和固体形式 |
| CN113278023B (zh) * | 2021-07-22 | 2021-10-15 | 上海睿跃生物科技有限公司 | 含氮杂环化合物及其制备方法和应用 |
| US20250129067A1 (en) * | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2024171143A1 (en) | 2023-02-17 | 2024-08-22 | Assia Chemical Industries Ltd. | Salts and solid forms of elenestinib |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61238784A (ja) | 1985-04-17 | 1986-10-24 | Sumitomo Seiyaku Kk | コハク酸イミド誘導体及びその酸付加塩 |
| IL144977A0 (en) * | 1999-05-21 | 2002-06-30 | Bristol Myers Squibb Co | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| MXPA02003436A (es) | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
| SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| PL219736B1 (pl) | 2002-04-23 | 2015-07-31 | Bristol Myers Squibb Co | Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie |
| TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| UA81453C2 (en) | 2003-02-27 | 2008-01-10 | Pyrazolopyridine derivates | |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| EP1755607A2 (en) | 2004-04-29 | 2007-02-28 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| PL1973910T3 (pl) | 2006-01-27 | 2013-11-29 | Shanghai hengrui pharmaceutical co ltd | Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej |
| SI2041138T1 (sl) | 2006-07-07 | 2014-08-29 | Bristol-Myers Squibb Company | Pirolotriazin kinazni inhibitorji |
| US8415340B2 (en) | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| AU2009226024B2 (en) | 2008-03-20 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| CA2764818A1 (en) | 2009-06-08 | 2010-12-16 | California Capital Equity, Llc | Triazine derivatives and their therapeutical applications |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| AU2011218167B2 (en) | 2010-02-17 | 2014-07-10 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN102040494A (zh) | 2010-11-12 | 2011-05-04 | 西北师范大学 | 对氟苯甲醛的制备方法 |
| WO2013004551A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| AR110963A1 (es) | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
| KR102398659B1 (ko) | 2017-03-17 | 2022-05-16 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
| WO2018183712A1 (en) * | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN109400610A (zh) | 2017-08-18 | 2019-03-01 | 浙江海正药业股份有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途 |
| CN108191874B (zh) | 2018-01-16 | 2019-11-29 | 成都施贝康生物医药科技有限公司 | 一种C-Kit抑制剂及其应用 |
| CN109970745B (zh) | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| CR20200588A (es) | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| WO2020102095A1 (en) | 2018-11-12 | 2020-05-22 | Blueprint Medicines Corporation | Avapritinib resistance of kit mutants |
| PE20211756A1 (es) | 2018-12-20 | 2021-09-07 | Pfizer | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß |
| SG11202111244XA (en) | 2019-04-12 | 2021-11-29 | Blueprint Medicines Corp | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| CN110950872A (zh) | 2019-12-25 | 2020-04-03 | 武汉九州钰民医药科技有限公司 | 制备靶向抗癌药avapritinib的方法 |
| CN110938077B (zh) | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
| WO2022081626A1 (en) | 2020-10-14 | 2022-04-21 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
-
2020
- 2020-04-08 SG SG11202111244XA patent/SG11202111244XA/en unknown
- 2020-04-08 MX MX2021012469A patent/MX2021012469A/es unknown
- 2020-04-08 MA MA55604A patent/MA55604B1/fr unknown
- 2020-04-08 EP EP24170331.3A patent/EP4424312A3/en active Pending
- 2020-04-08 MY MYPI2021006079A patent/MY209048A/en unknown
- 2020-04-08 HU HUE20721083A patent/HUE067299T2/hu unknown
- 2020-04-08 LT LTEPPCT/US2020/027177T patent/LT3953357T/lt unknown
- 2020-04-08 PE PE2021001699A patent/PE20212331A1/es unknown
- 2020-04-08 HR HRP20240702TT patent/HRP20240702T1/hr unknown
- 2020-04-08 SM SM20240229T patent/SMT202400229T1/it unknown
- 2020-04-08 US US17/602,770 patent/US12552795B2/en active Active
- 2020-04-08 SI SI202030454T patent/SI3953357T1/sl unknown
- 2020-04-08 JP JP2021560255A patent/JP7600140B2/ja active Active
- 2020-04-08 IL IL287168A patent/IL287168B2/en unknown
- 2020-04-08 ES ES20721083T patent/ES2980811T3/es active Active
- 2020-04-08 US US16/842,969 patent/US10829493B2/en active Active
- 2020-04-08 CA CA3136802A patent/CA3136802A1/en active Pending
- 2020-04-08 BR BR112021020441A patent/BR112021020441A2/pt unknown
- 2020-04-08 TW TW109111858A patent/TWI857043B/zh active
- 2020-04-08 DK DK20721083.2T patent/DK3953357T3/da active
- 2020-04-08 MD MDE20220189T patent/MD3953357T2/ro unknown
- 2020-04-08 FI FIEP20721083.2T patent/FI3953357T3/fi active
- 2020-04-08 PT PT207210832T patent/PT3953357T/pt unknown
- 2020-04-08 PL PL20721083.2T patent/PL3953357T3/pl unknown
- 2020-04-08 AU AU2020272743A patent/AU2020272743B2/en active Active
- 2020-04-08 WO PCT/US2020/027177 patent/WO2020210293A1/en not_active Ceased
- 2020-04-08 EP EP20721083.2A patent/EP3953357B1/en active Active
- 2020-04-08 KR KR1020217036868A patent/KR102875260B1/ko active Active
- 2020-04-08 RS RS20240664A patent/RS65644B1/sr unknown
- 2020-04-08 CN CN202080042732.0A patent/CN113939515B/zh active Active
-
2021
- 2021-04-08 PH PH1/2021/552568A patent/PH12021552568A1/en unknown
- 2021-10-12 CL CL2021002656A patent/CL2021002656A1/es unknown
- 2021-10-21 ZA ZA2021/08104A patent/ZA202108104B/en unknown
- 2021-11-09 CO CONC2021/0015113A patent/CO2021015113A2/es unknown
- 2021-11-12 EC ECSENADI202180096A patent/ECSP21080096A/es unknown
-
2024
- 2024-12-03 JP JP2024210028A patent/JP2025029094A/ja active Pending
-
2026
- 2026-01-22 US US19/456,134 patent/US20260138986A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240702T1 (hr) | Pripravci i metode za liječenje bolesti posredovanih kitom i pdgfra | |
| Buggins et al. | The effects of pharmaceutical excipients on drug disposition | |
| JP2022526850A5 (enExample) | ||
| Emami et al. | Quinolones: recent structural and clinical developments | |
| JP2016028090A5 (enExample) | ||
| Desai et al. | Synthesis and antimicrobial activity of novel quinazolinone–thiazolidine–quinoline compounds | |
| EA201270738A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
| JP2015044834A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| ME02879B (me) | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola | |
| HRP20180331T1 (hr) | Spojevi n-pirolidinil, n'pirazolil- urea, tiourea, gvanidin i cijanogvanidin kao inhibitori trka kinaze | |
| JP2011126896A5 (enExample) | ||
| NO20092231L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| CN111836807A (zh) | 氧杂螺环类化合物及其制备方法和用途 | |
| CN111902417A (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
| ATE495174T1 (de) | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3 yl)acetamidderivate und verwandte verbindungen als antipilzmittel | |
| JP2016503785A5 (enExample) | ||
| HRP20171041T1 (hr) | Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže | |
| Szulc et al. | Novel analogs of De-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents | |
| JP2012502915A5 (enExample) | ||
| MY145647A (en) | (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states) |